Has David Goldfarb, MD received payments from drug or device companies?

Yes. Drug and device makers reported $86,536 in general payments to David Goldfarb, MD across 111 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean David Goldfarb, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about David Goldfarb, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

David Goldfarb, MD

Nephrology · New York, NYNPI 1629018908

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $63,541 of the $86,536 with a category attached, or 73.4%. 11 manufacturers reported payments, led by Novo Nordisk at 25.7% of the total. Reporting peaked in 2024 at $24,376 and has fallen 73.8% since, to $6,393 in 2025. Among nephrology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$86,536in general payments, 2019–2025

Across 111 payments — averaging $779.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$22K
Alnylam Pharmaceuticals Inc.$22K
AstraZeneca$14K
Travere Therapeutics, Inc.$8K
Novo Nordisk AS$8K
Sumitomo Pharma Co., Ltd.$4K
plus $9K from 5 others

$725,626in research payments, 2019–2025

Across 235 payments — averaging $3087.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Travere Therapeutics, Inc.$214K
Akebia Therapeutics Inc$208K
Novo Nordisk AS$193K
Alnylam Pharmaceuticals Inc.$78K
Novo Nordisk US Research & Development, Inc.$19K
Gilead$14K

What the payments were for

Consulting fees$63,54173%
Speaking & faculty fees$5,3156%
Travel & lodging$15,31918%
Food & beverage$2,3513%
Education$90%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	32	$22,275
Alnylam Pharmaceuticals Inc.	25	$21,686
AstraZeneca	23	$13,646
Travere Therapeutics, Inc.	16	$8,458
Novo Nordisk AS	6	$7,549
Sumitomo Pharma Co., Ltd.	2	$4,125
Sanofi US Services Inc.	1	$2,855
Novo Nordisk Health Care AG	1	$2,700
Amgen	2	$2,629
Eli Lilly	1	$500
Vifor Pharma, Inc.	2	$111

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

OXLUMO$16,991
LOKELMA$13,299
(815) Thiola$5,784
KRYSTEXXA$2,629
Rivfloza$122

How this compares

$86,536 in reported general payments places this provider in the 95th percentile of 935 nephrology providers in New York.

See all nephrology providers in New York →

Medicare billing

Part B allowed, 2024

$11,132

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Thiola EcTiopronin	16	$178,223
ThiolaTiopronin	11	$139,015
Potassium Citrate ErPotassium Citrate	199	$35,620
Butorphanol Tartrate	15	$8,920
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	13	$809
Indapamide	41	$690
Chlorthalidone	31	$504
Potassium Chloride	13	$282
Allopurinol	21	$238
Lisinopril	11	$172
Furosemide	13	$26

Paid to pharmacies, not to this prescriber.

Other nephrology in New York

Gerald AppelNew York$842K
Richard ChanNew York$514K
Steven CocaNew York$445K
Jai RadhakrishnanNew York$369K
Girish NadkarniNew York$281K
James ChevalierNew York$202K
David CharytanNew York$164K
Kirk CampbellNew York$152K
Andrew BombackNew York$106K
Alan PerlmanNew York$101K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →